Sun Pharma Advanced Research Company Ltd. NSE: SPARC | BSE: 532872

Download real time

140.09 -0.18 (-0.13%)

41.87% Fall from 52W High

155.7K

NSE+BSE Volume

NSE 29 Aug, 2025 3:31 PM (IST)

Sun Pharma Advanced Research Company Ltd. share price target

Latest broker research reports with buy, sell, hold recommendations along with forecast share price targets and upside. Browse thousands of reports and search by company or the broker.

Reco - This broker has downgraded this stock from it's previous report.
(eg. - Buy->Hold)

Target - Broker has maintained previous recommendation but reduced share price target.

Reco - This broker has upgraded this stock from it's previous report.
(eg. - Sell->Hold)

Target - Broker has maintained previous recommendation but increased share price target.

Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report		Discuss
	10 Dec 2019	Sun Pharma Advanced	Prabhudas Lilladhar	140.09		163.05 (-14.08%)		Not Rated	pdf post cache		Broker Report Event Update Prabhudas Lilladhar Sun Pharma Advanced Research (SPARC) received a resolution for Abraxane as Abraxis Biosciences LCC withdrew its infringement claims yesterday in the US District Court of New Jersey. Earlier, Abraxis filed a complaint in the court that the NDA (505b2) of SPARC (Abraxane) has breached patent and sued them for its filing of Taclantis (Paclitaxel Injection concentrate for Suspension) in the District Court. While the event is a positive development in February FY20E (filed with USFDA in June2019). SPARC will have three potential annual sales of US$25-30m. Not Rated SPARC evaluating marketing options... pdf Copy Link Share on Share on Share on Share on Alert
	11 Jun 2015	Sun Pharma Advanced	Karvy	140.09		398.25 (-64.82%)			pdf post cache		Broker Report SPARC Investor Presentation & Conference Call Update (Jun 11, 2015) Karvy Four New Products Added to Pipeline; Xelpros NDA Submission CompletedSPARC replied to the Complete Response Letter (CRL) from USFDA for Xelpros (Latanoprost BAK-Free) in April 2015, this completes the full submission of NDA for Xelpros. pdf Copy Link Share on Share on Share on Share on Alert
	11 Jun 2015	Sun Pharma Advanced	Reliance Securities	140.09		398.20 (-64.82%)			pdf post cache		Broker Report SPARC-Event Update Reliance Securities Sun has discontinued certain programs after commercial assessment of the molecules and found them unviable on economic and commercial standpoints. These include candidates such as Venlafexine ER 300mg, Sun... pdf Copy Link Share on Share on Share on Share on Alert
	03 Mar 2015	Sun Pharma Advanced	Karvy	140.09		411.65 (-65.97%)			pdf post cache		Broker Report Sun Pharma Advanced Research Company Ltd. (SPARC) - Initiating Note (Mar 03, 2015) Karvy Innovating New Drug Delivery Systems and New Drugs: Sun Pharma Advanced Research Company (SPARC) is primarily involved in new drug discovery, research and development, unlike other Indian pharma firms that mainly manufacture generic medicines. SPARC has been granted 20 US patents for various inventions. The company has 11 novel products in pipeline at various development stages for launch in US. Some products have been launched in India. pdf Copy Link Share on Share on Share on Share on Alert

* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.

Advisor Screeners